Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Milestones in the Blood Based Biomarkers Market’s Growth Trajectory From 2025 To 2034?
The market for blood-based biomarkers has seen swift advancement in the past few years. The market’s scale is projected to amplify from $23.13 billion in 2024 to hit $25.83 billion in 2025, with a compound annual growth rate (CAGR) of 11.6%. The surge experienced in the historical timeframe can be accredited to the escalating incidence of cancer globally, the growing uptake of personalized treatment, augmented investments in biomarker studies, the broadening of clinical trials centered on biomarkers, and the escalating approvals for companion diagnostics.
The market size of blood-based biomarkers is anticipated to experience a swift expansion in the coming years, escalating to $40.66 billion by 2029 at a compound annual growth rate (CAGR) of 12.0%. This expected growth during the forecast period can be credited to the broadening of AI and machine learning in biomarker studies, a surge in the necessity for early disease identification, expansion of telemedicine and remote diagnostics, a growing incidence of chronic ailments, and a boost in health awareness among consumers. Key trends to watch during this projected period encompass AI-aided biomarker discovery, advancements in liquid biopsy, incorporation of multi-omics, the emergence of point-of-care (POC) testing devices and innovations in next-generation sequencing (NGS).
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Blood Based Biomarkers Market?
The escalation in instances of cardiovascular ailments is predicted to invigorate the expansion of the blood-based biomarkers domain. These cardiovascular issues represent a cluster of maladies impacting the heart and circulatory system, encompassing maladies like coronary artery disease, heart failure, and stroke. The surge in these diseases broadly stems from the upswing in risk factors such as unhealthy nutrition and mounting obesity statistics. Blood-based biomarkers contribute to the identification and monitoring of cardiovascular conditions by offering an understanding of disease progression, risk evaluation, and response to treatment via detectable substances in the bloodstream. For instance, the National Center for Biotechnology Information, a government entity based in the U.S., declared a worldwide health study enterprise in September 2024. The forecasts signified a 90% swell in cardiovascular disease prevalence from 2025 until 2050, with the conjectured cardiovascular casualties touching the 35.6 million mark by 2050. Consequently, the escalating instances of cardiovascular disorders are steering the expansion of blood-based biomarkers.
Which Primary Segments of the Blood Based Biomarkers Market Are Driving Growth and Industry Transformations?
The blood based biomarkers market covered in this report is segmented –
1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers
2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies
3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications
4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users
Subsegments:
1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions
2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins
3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels
4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells
5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24176&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Blood Based Biomarkers Market?# Market?
North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Blood Based Biomarkers Market?
Leading enterprises in the market for blood-based biomarkers are concentrating on enhancing their technologies, specifically in the development of high-precision blood biomarker exams to support physicians in diagnosing Alzheimer’s disease. A blood biomarker test with high accuracy is a diagnostic instrument that uses distinct biomarkers from the blood to detect diseases or observe health conditions with superior precision and dependability. For example, Quanterix, a life sciences organization based in the US, launched a high-accuracy blood biomarker test, LucentAD p-Tau 217, in October 2023. This test is designed to aid doctors in diagnosing Alzheimer’s disease in adults demonstrating cognitive impairment. The test measures the p-Tau 217, a phosphorylated tau protein that is a biomarker linked strongly to Alzheimer’s disease pathology, especially in regard to amyloid accumulation in the brain. The LucentAD p-Tau 217 test has an accuracy above 90%, making it meet the strict diagnostic criteria. However, it should be applied alongside other diagnostic instruments, not as an individual test.
View the full report here:
https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report
What Parameters Are Used to Define the Blood Based Biomarkers Market?
Blood-based biomarkers are measurable substances in the blood that indicate the presence or progression of a disease, as well as an individual’s response to treatment. Their primary purpose is to enable early disease detection, guide personalized treatment decisions, and monitor treatment efficacy with minimal invasiveness.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24176
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model